Japan approval expands Actos combination uses in diabetes
This article was originally published in Scrip
Executive Summary
Takeda's oral antidiabetic Actos (pioglitazone) has received formal final approval in Japan for use as a concomitant therapy with insulin. The thiazolidinedione insulin sensitiser is now indicated for use in type 2 diabetics whose disease is inadequately controlled by diet and exercise plus insulin.